Literature DB >> 25808135

Molecular modeling study of the induced-fit effect on kinase inhibition: the case of fibroblast growth factor receptor 3 (FGFR3).

Yan Li1, Michel Delamar, Patricia Busca, Guillaume Prestat, Laurent Le Corre, Laurence Legeai-Mallet, RongJing Hu, Ruisheng Zhang, Florent Barbault.   

Abstract

Tyrosine kinases are a wide family of targets with strong pharmacological relevance. These proteins undergo large-scale conformational motions able to inactivate them. By the end of one of these structural processes, a new cavity is opened allowing the access to a specific type of inhibitors, called type II. The kinase domain of fibroblast growth factor receptor 3 (FGFR3) falls into this family of kinases. We describe here, for the first time, its inactivation process through target molecular dynamics. The transient cavity, at the crossroad between the DFGout and Cα helix out inactivation is herein explored. Molecular docking calculations of known ligands demonstrated that type II inhibitors are able to interact with this metastable transient conformation of FGFR3 kinase. Besides, supplemental computations were conducted and clearly show that type II inhibitors drive the kinase inactivation process through specific stabilization with the DFG triad. This induced-fit effect of type II ligands toward FGFR3 might be extrapolated to other kinase systems and provides meaningful structural information for future drug developments.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25808135     DOI: 10.1007/s10822-015-9841-8

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  70 in total

1.  Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation.

Authors:  Araz Jakalian; David B Jack; Christopher I Bayly
Journal:  J Comput Chem       Date:  2002-12       Impact factor: 3.376

Review 2.  Protein kinases--the major drug targets of the twenty-first century?

Authors:  Philip Cohen
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

3.  Insights into MAPK p38alpha DFG flip mechanism by accelerated molecular dynamics.

Authors:  Federico Filomia; Francesca De Rienzo; M Cristina Menziani
Journal:  Bioorg Med Chem       Date:  2010-07-29       Impact factor: 3.641

4.  Molecular modeling studies of N-substituted pyrrole derivatives--potential HIV-1 gp41 inhibitors.

Authors:  Cátia Teixeira; Florent Barbault; Joseph Rebehmed; Kun Liu; Lan Xie; Hong Lu; Shibo Jiang; BoTao Fan; François Maurel
Journal:  Bioorg Med Chem       Date:  2008-01-28       Impact factor: 3.641

Review 5.  Long-timescale molecular dynamics simulations of protein structure and function.

Authors:  John L Klepeis; Kresten Lindorff-Larsen; Ron O Dror; David E Shaw
Journal:  Curr Opin Struct Biol       Date:  2009-04-08       Impact factor: 6.809

6.  Calculation of electrostatic effects at the amino terminus of an alpha helix.

Authors:  D Sitkoff; D J Lockhart; K A Sharp; B Honig
Journal:  Biophys J       Date:  1994-12       Impact factor: 4.033

Review 7.  The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases.

Authors:  L N Johnson; E D Lowe; M E Noble; D J Owen
Journal:  FEBS Lett       Date:  1998-06-23       Impact factor: 4.124

8.  Is inhibition process better described with MD(QM/MM) simulations? The case of urokinase type plasminogen activator inhibitors.

Authors:  Florent Barbault; François Maurel
Journal:  J Comput Chem       Date:  2012-01-13       Impact factor: 3.376

9.  Molecular dynamics simulations of 2-amino-6-arylsulphonylbenzonitriles analogues as HIV inhibitors: interaction modes and binding free energies.

Authors:  Rongjing Hu; Florent Barbault; François Maurel; Michel Delamar; Ruisheng Zhang
Journal:  Chem Biol Drug Des       Date:  2010-10-13       Impact factor: 2.817

10.  Improved side-chain torsion potentials for the Amber ff99SB protein force field.

Authors:  Kresten Lindorff-Larsen; Stefano Piana; Kim Palmo; Paul Maragakis; John L Klepeis; Ron O Dror; David E Shaw
Journal:  Proteins       Date:  2010-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.